Controversy surrounds the use of polypills in the primary prevention of cardiovascular disease, particularly in relation to which individuals should be targeted for treatment. Coronary artery calcium imaging has been presented as being of potential benefit in excluding those who are least likely to benefit from such treatment.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Wald, N. J. & Law, M. R. A strategy to reduce cardiovascular disease by more than 80%. BMJ 326, 1419 (2003).
Bittencourt, M. S. et al. Polypill therapy, subclinical atherosclerosis, and cardiovascular events—implications for the use of preventive pharmacotherapy: Multi-Ethnic Study of Atherosclerosis (MESA). J. Am. Coll. Cardiol. http://dx.doi.org/10.1016/j.jacc.2013.08.1640.
Lafeber, M. et al. The cardiovascular polypill in high-risk patients. Eur. J. Prev. Cardiol. 19, 1234–1242 (2012).
Yeboah, J. et al. Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals. JAMA 308, 788–795 (2012).
Rana, J. S. et al. Comparative value of coronary artery calcium and multiple blood biomarkers for prognostication of cardiovascular events. Am. J. Cardiol. 109, 1449–1453 (2012).
Rozanski, A. et al. Impact of coronary artery calcium scanning on coronary risk factors and downstream testing: the EISNER (Early Identification of Subclinical Atherosclerosis by Noninvasive Imaging Research) prospective randomized trial. J. Am. Coll. Cardiol. 57, 1622–1632 (2011).
Thom, S. et al. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial. JAMA 310, 918–929 (2013).
Law, M. R. & Wald, N. J. Risk factor thresholds: their existence under scrutiny. BMJ 324, 1570–1576 (2002).
Mendis, S. et al. WHO study on Prevention of REcurrences of Myocardial Infarction and StrokE (WHO-PREMISE). Bull. World Health Organ. 83, 820–829 (2005).
Morris, Z. S., Wooding, S. & Grant, J. The answer is 17 years, what is the question: understanding time lags in translational research. J. R. Soc. Med. 104, 510–520 (2011).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
A. Rodgers was Principal Investigator of one of the previous polypill clinical trials discussed in this paper. The George Institute for Global Health obtained a license for the polypill used in this and other trials, following a decision by the manufacturer not to launch the products because of uncertainty in regulatory requirements. R. Webster declares no competing interests.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Webster, R., Rodgers, A. Coronary artery calcium and polypill therapy. Nat Rev Cardiol 11, 7–8 (2014). https://doi.org/10.1038/nrcardio.2013.185
Published:
Issue date:
DOI: https://doi.org/10.1038/nrcardio.2013.185
This article is cited by
-
Optimizing treatment benefit: individualized therapy or the polypill?
Nature Reviews Cardiology (2014)
-
Personalization of therapy and polypills
Nature Reviews Cardiology (2014)
